Valganciclovir prophylaxis extension from 3 to 6 months in high‐risk pancreas‐transplant recipients does not impact incidence of cytomegalovirus infection at 12 months

Problem Incidence and impact of CMV infection in pancreas‐transplant recipients (PTRs) in the valganciclovir prophylaxis era has not been completely elucidated. Methods Adult D+/R‐ PTRs were divided into a current era (1/1/2011‐12/31/17; 6‐month PPX) and a historic era (1/1/2003‐12/31/09; 3‐month PP...

Full description

Saved in:
Bibliographic Details
Published in:Clinical transplantation 2021-08, Vol.35 (8), p.e14379-n/a
Main Authors: Jorgenson, Margaret R., Marka, Nicholas, Leverson, Glen E., Smith, Jeannina A., Odorico, Jon S.
Format: Article
Language:English
Subjects:
graft survival
infection and infectious agents
patient survival
preventive healthcare
viral: Cytomegalovirus
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Problem Incidence and impact of CMV infection in pancreas‐transplant recipients (PTRs) in the valganciclovir prophylaxis era has not been completely elucidated. Methods Adult D+/R‐ PTRs were divided into a current era (1/1/2011‐12/31/17; 6‐month PPX) and a historic era (1/1/2003‐12/31/09; 3‐month PPX). Primary objective: effect of prophylaxis extension on the incidence of CMV infection. Secondary objective: impact of extension on valganciclovir‐related toxicity (leukopenia) and transplant outcomes. Results There were 177 D+/R‐ PTRs in the study period (historic:98, current:79). Prophylaxis extension resulted in significant reduction of CMV infection from 25.4% to 10.9% at 6 months, (57% reduction, p = .021). However, 1‐year rates of CMV infection (historic:31% vs current:36%) and end‐organ disease (historic:7.7% vs current:6.9%) were not different (p = .93). Prophylaxis extension significantly increased leukopenia (white blood cell count
ISSN:0902-0063
1399-0012
DOI:10.1111/ctr.14379